REO 009

Intravenous Administration of REOLYSIN® in Combination with Gemcitabine for Patients with Advanced Malignancies

In June 2009, Oncolytics announced positive results of its completed UK trial using intravenous administration of REOLYSIN^® in combination with gemcitabine. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and/or clinical response, and five patients had stable disease (SD) for between four and eight cycles, for a total disease control rate (CR (complete response) + PR + SD) of 70%.
 
The primary objective of the trial was to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN^® when administered in combination with gemcitabine. Secondary objectives included the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of antitumor activity.
 
 
Links:

• A Phase I Study of the Combination of Intravenous REOLYSIN^® (Wild-Type Reovirus) and Gemcitabine (REO-GEM) in Patients with Advanced Cancer (PDF)

• November 24, 2010: A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer (PDF)

• March 25, 2009: Oncolytics Biotech Inc. Completes Enrollment in Combination REOLYSIN^®/Gemcitabine Trial (Press Release)